Loading
A phase 3 trial testing TQB3454 in biliary tract cancer, active and no longer recruiting.
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma is a phase 3 interventional study registered as NCT05987358, led by Chia Tai Tianqing Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of TQB3454 Tablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation. Planned enrolment is 165 participants (estimated). The study started in 2023-09-21 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/